---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-037234"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-09-21T20:05:54+00:00"
generated_at: "2026-09-21T20:07:51.120755+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "low"
source: SEC EDGAR
---

# PDS Biotech updates corporate presentation deck; no new trial or financial data disclosed

## Summary
- On September 21, 2026, PDS Biotechnology (NASDAQ: PDSB) posted an updated corporate presentation.
- Deck titled 'Overview of PDS Biotech Drug Development Programs (Oncology)' — oncology immunotherapy focus.
- Exhibit text provided contains only the cover slide; no dosing, efficacy, or financial figures included.
- Filing signed by Frank Bedu-Addo, Ph.D., President and CEO.

## SEC filing metadata
- accession: 0001140361-26-037234
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-09-21T20:05:54+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126037234/0001140361-26-037234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126037234/ef20082538_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-037234
- JSON: https://secwatch.observer/filing/0001140361-26-037234.json
- Plain text: https://secwatch.observer/filing/0001140361-26-037234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.